Skip to content
TriangleGet started
← Full study record

NCT01724177 · FLOW

Participant flow

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma · Source last updated 2018-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Lenalidomide 25 mg administered by mouth (PO) once daily (QD) until progressive disease or unacceptable toxicity
    id
    FG000
    title
    Lenalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Progressive disease or Relapsed Disease
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Nervous participant
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Serious Adverse Event Related
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. comment
        Safety Population includes participants who received at least one dose of lenalidomide
        group Id
        FG000
        num Subjects
        26
      type
      Safety Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
This study included Japanese participants with relapsed or recurrent adult T-cell leukemia (ATL) who had previously received anti- ATL chemotherapy and who were categorized as having acute-lymphoma or unfavorable chronic-type ATL.
Complete source fields
groups
  1. description
    Lenalidomide 25 mg administered by mouth (PO) once daily (QD) until progressive disease or unacceptable toxicity
    id
    FG000
    title
    Lenalidomide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Progressive disease or Relapsed Disease
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Nervous participant
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Serious Adverse Event Related
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. comment
        Safety Population includes participants who received at least one dose of lenalidomide
        group Id
        FG000
        num Subjects
        26
      type
      Safety Population
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
This study included Japanese participants with relapsed or recurrent adult T-cell leukemia (ATL) who had previously received anti- ATL chemotherapy and who were categorized as having acute-lymphoma or unfavorable chronic-type ATL.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice